Search

There is an ongoing aim to replace animal and in vitro laboratory models with in silico methods. Such replacement requires the successful validation and comparably good performance of the alternative methods. We have developed an in silico prediction system for human clinical pharmacokinetics, based on machine learning, conformal prediction and a new physiologically-based pharmacokinetic model, i.e. ANDROMEDA. The objectives of this study were: a) to evaluate how well ANDROMEDA predicts the human clinical pharmacokinetics of a previously proposed benchmarking data set comprising 24 physicochemically diverse drugs and 28 small drug molecules new to the market in 2021; b) to compare its predictive performance with that of laboratory methods; and c) to investigate and describe the pharmacokinetic characteristics of the modern drugs. Median and maximum prediction errors for the selected major parameters were ca 1.2 to 2.5-fold and 16-fold for both data sets, respectively. Prediction accuracy was on par with, or better than, the best laboratory-based prediction methods (superior performance for a vast majority of the comparisons), and the prediction range was considerably broader. The modern drugs have higher average molecular weight than those in the benchmarking set from 15 years earlier ( ca 200 g/mol higher), and were predicted to (generally) have relatively complex pharmacokinetics, including permeability and dissolution limitations and significant renal, biliary and/or gut-wall elimination. In conclusion, the results were overall better than those obtained with laboratory methods, and thus serve to further validate the ANDROMEDA in silico system for the prediction of human clinical pharmacokinetics of modern and physicochemically diverse drugs.

The gastrointestinal uptake of macrocyclic compounds is not fully understood. Here we applied our previously validated integrated system based on machine learning and conformal prediction to predict the passive fraction absorbed (f

The ANDROMEDA software, based on machine learning, conformal prediction and a new physiologically-based pharmacokinetic model, was used to predict and characterize the human clinical pharmacokinetics of 30 selected modern small antibiotic compounds (investigational and marketed drugs). A majority of clinical pharmacokinetic data was missing. ANDROMEDA successfully filled this gap. Most antibiotics were predicted and measured to have limited permeability, good metabolic stability and multiple elimination pathways. According to predictions, most of the antibiotics are mainly eliminated renally and biliary and every other antibiotic is mainly eliminated via the renal route. Mean prediction errors for steady state volume of distribution, unbound fraction in plasma, renal and total clearance, oral clearance, fraction absorbed, fraction excreted renally, oral bioavailability and half-life were 1.3- to 2.3-fold. The overall median and maximum prediction errors were 1.5- and 4.8-fold, respectively, and 92 % of predictions had

The ANDROMEDA toolkit for prediction of human clinical pharmacokinetics, based on machine learning, conformal prediction and a new physiologically-based pharmacokinetic model, was used to predict and characterize the human clinical pharmacokinetics of 12 small anticancer drugs marketed in 2021 and 2022 (molecular weight 355 to 1326 g/mol). The study is part of a series of software validations. A majority of clinical pharmacokinetic data was missing. ANDROMEDA successfully filled this gap. Most drugs were predicted/measured to have relatively complex pharmacokinetics, with limited passive permeability+efflux, high degree of plasma protein binding, significant gut-wall elimination and food interaction, biliary excretion and/or limited dissolution potential. Median, mean and maximum prediction errors for steady state volume of distribution, unbound fraction in plasma, blood-to-plasma concentration ratio, hepatic, renal and total clearance, fraction absorbed, oral bioavailability, half-life and degree of food interaction were 1.6-, 2.4- and 17-fold, respectively. Less than 3-fold errors were found for 78 % of predictions. Results are consistent with those obtained in previous validation studies and are better than with the best laboratory-based prediction methods, which validates ANDROMEDA for predictions of human clinical pharmacokinetics of modern small anticancer drugs with multi-mechanistical and challenging pharmacokinetics.

Volume of distribution at steady state (Vss) is an important pharmacokinetic endpoint. In this study we apply machine learning and conformal prediction for human Vss prediction, and make a head-to-head comparison with rat-to-man scaling, allometric scaling and the Rodgers-Lukova method on combined in silico and in vitro data, using a test set of 105 compounds with experimentally observed Vss.The mean prediction error and % with

IntroductionThe ANDROMEDA software by Prosilico has previously been successfully applied and validated for predictions of absorption characteristics of small drugs in man. The effects of fat food on the gastrointestinal uptake and systemic exposure of drugs have, however, not yet been evaluated with the software.Objective and MethodologyThe main objective was to use ANDROMEDA to predict area under the plasma concentration-time curve ratios in the fed (fat food) and fasted states (AUCfed/AUCfast) for small drugs marketed in 2021 and compare results with corresponding measured clinical estimates. A secondary aim was to make a similar evaluation for a set of selected older small drugs with no and significant food interaction.Results17 new drugs with observed AUCfed/AUCfastbetween 0.4 and 2.0 were found. In addition, 18 older drugs with low (0.5), moderate (1) and high (3.1-5.5) AUCfed/AUCfastwere selected. Predicted AUCfed/AUCfast(for all drugs) had mean, median and maximum errors of 1.4-, 1.1- and 3.9-fold, respectively, and the predictive accuracy (correlation between predicted and observed AUCfed/AUCfast; Q2) was 0.35. For new small drugs, the Q2was 0.41. All 10 new drugs with AUCfed/AUCfastbetween 0.8 and 1.25 were predicted to have AUCfed/AUCfastbetween 0.6 and 1.5 and all 4 new drugs with AUCfed/AUCfastfed/AUCfastfed/AUCfast≥1.25).ConclusionThe results validate ANDROMEDA for prediction of fat food-drug interaction size for small drugs in man. Major advantages with the methodology include that results are produced directly from molecular structure and oral dose and an adequate level of predictive accuracy.

IntroductionSome prodrugs are developed in order to improve gastrointestinal absorption properties such as permeability and solubility/dissolution. Prediction of the uptake of prodrugs and their drugs is challening for reasons including gastrointestinal hydrolysis and active transport.Objective and MethodologyThe objective was to use the ANDROMEDA software by Prosilico to predict absorption characteristics - passive fraction absorbed (fa,passive), dose-adjusted dissolution potential (fdiss) and total fa(fa) - of prodrugs and their drugs (including drugs and their active metabolites), and to evaluate how they differ between prodrugs and drugs and the predictive accuracy of the software.Results70 prodrug-drug pairs were found and selected for the study. The mean predicted fa,passiveand fdissfor the prodrugs were 0.74 and 0.94, respectively. Corresponding estimates for the drugs were 0.72 and 0.98, respectively. For non-hydrolyzed prodrugs, the median relative and absolute prediction errors for fawere 1.17-fold and 0.08, respectively. Corresponding values for drugs were 1.11-fold and 0.07, respectively. The correlation between predicted and observed fafor non-hydrolyzed ester prodrugs and drugs combined (predictive accuracy) was 0.6.ConclusionProdrugs and drugs had similar average predicted fa,passiveand fdiss, and most had or were predicted to have at least 50 % fa. The fafor about 1/3 of non-hydrolyzed prodrugs was higher than for corresponding drugs, showing successful prodrug design. Adequate prediction accuracy validates ANDROMEDA for prediction of prodrug and drug absorption in man.

IntroductionConformal prediction (CP) methodology sits on top of machine learning methods and produces prediction confidence intervals that depend on how “strange” (non-conforming) test compounds are compared to training set compounds. CP has previously been successfully applied for prediction of steady-state volume of distribution (Vss) in humans, with 69 % of observations within the prediction interval at a 70 % confidence level. We have developed CP models for a variety of human pharmacokinetic (PK) parameters and validated their predictive accuracy (predictedvsobserved estimates), but not validated prediction confidence intervals for them. The main objective of this study was to predict 70 % confidence intervals for Vss, unbound fraction in plasma (fu), intrinsic metabolic clearance (CLint), fraction absorbed passively (fa,passive) and maximum fraction dissolved (fdiss) for a variety of compounds in man and investigate the consistency between prediction intervals and observed/measured values.MethodologyCP models featured in the ANDROMEDA software by Prosilico were used for prediction of 70 % confidence intervals of Vss, fu, CLint, fa,passiveand fdissfor compounds from different chemical classes and with broad physicochemical variety and for small drugs marketed in 2021.Results70 % prediction confidence intervals for 217, 117, 117, 89 and 89 compounds were produced for Vss, fu, CLint, fa,passiveand fdiss, respectively. 78 % (expected 70 %) of observed data were within 70 % confidence intervals for the parameters. 70 % of predictions of Vss, fu, CLintfa,passiveand fdissare expected to have errors of maximally 2-, 4- and 6-fold and 7 and 12 %, respectively, which is in line with prediction errors. These findings validate the CP methodology.ConclusionIn conclusion, the results further validate CP models and confidence intervals of ANDROMEDA for prediction of human PK.

IntroductionIn vitromeasurements and predictions of human clinical pharmacokinetics (PK) are sometimes hindered and made impossible due to factors such as extensive binding to materials, low methodological sensitivity and large variability.MethodsThe objective was to find compounds out of reach forin vitroPK-methods and (if possible) predict corresponding human clinical estimates using the ANDROMEDA by Prosilico software.In vitromethods selected for the investigation were human microsomes and hepatocytes for measuring and predicting intrinsic hepatic metabolic clearance (CLint), Caco-2 cells for measuring apparent intestinal permeability (Papp) for prediction of fraction absorbed (fa), plasma for measurement and estimation of unbound fraction (fu), and water and buffers for measuring solubility (S) for prediction ofin vivodissolution potential (fdiss).Results and Conclusion73 non-quantifiablein vitroPK-measurements for 70 compounds were found in the literature: 40 for CLint, 8 for Papp, 11 for fuand 14 for S. ANDROMEDA was successful in predicting all corresponding clinical PK-estimates for the selection of compounds with non-quantifiablein vitroPK, and predicted estimates were generally in line with observedin vivodata and results/problems atin vitrolaboratories. Thus, ANDROMEDA is applicable for predicting human clinical PK for compounds out of reach for laboratory methods.

BackgroundPassive blood-brain barrier permeability (BBB Pe), fraction bound to brain tissue (fb,brain) and efflux by transport proteins MDR-1 and BCRP are essential determinants for the brain uptake and disposition of drugs.MethodsThe main objective of the study was to use the software ANDROMEDA by Prosilico to predict passive BBB Pe- and fb,brain-classes and MDR-1- and BCRP-specificities for various classes of antidepressants and for CNS-active small drugs marketed during 2020 and 2021, and then to position them according to a new 2-dimensional Brainavailability-Matrix (8 passive BBB Pex 4 fb,brainclasses, where class 11 has highest and 84 lowest values/brainavailability). Predicted estimates were used, except for cases where measured values were available.Results and ConclusionResults for 53 drugs show that adequate CNS uptake and disposition are achieved for compounds placed in the zones for low, moderate and high brainavailability, despite efflux. They also show that high brainavailability and efflux are common for CNS-active drugs and that modern CNS-active drugs generally have lower brainavailability than older antidepressive drugs. Furthermore, they demonstrate that ANDROMEDA by Prosilico and the new Brainavailability-Matrix are applicable for prediction, optimization and positioning of CNS uptake and disposition of drugs and drug candidates in man.

BackgroundPROTACs are comparably large and flexible compounds with limited solubility (S) and permeability (Pe). It is crucial to better understand, predict and optimize their human clinical pharmacokinetics (PK).MethodsThe main objective was to use the ANDROMEDA by Prosilico software to predict the human clinicalin vivodissolution potential (fdiss) and fraction absorbed (fa) of 23 PROTACs at a dose level of 50 mg and to explore whether there is any relationship betweenin vitroS andin silicopredictedin vivofdiss.ResultsIn silicopredictions showed that the PROTACs are effluxed by intestinal transporters and have limited fdiss(34 to 98 %), permeability and fa(13 to 58 %) in man. For some PROTACs this may be a major obstacle and jeopardize the clinical development programs, especially in cases of required high oral dose. A modest relationship betweenin vitroS and predictedin vivofdisswas demonstrated (R2=0.26). Predicted human fa(27 %) and oral bioavailability (20 %) of ARV-110 (a PROTAC with some availablein vivoPK data in rodents and man) were consistent with data obtained in rodents (estimated faapproximately 30-40 %; measured oral bioavailability 27-38 %). Laboratories were unable to quantify S for 7 (30 %) of the PROTACs. In contrast, ANDROMEDA could predict parameters for all.ConclusionANDROMEDA predicted fdissand fafor all the chosen PROTACs and showed limited fdiss, Peand faand dose-dependent fdissand fa. One available example shows promise for the applicability of ANDROMEDA for predicting biopharmaceutics of PROTACsin vivoin man. Weak to modest correlations between S and fdissand a considerable portion of compounds with non-quantifiable S limit the use of S-data to predict the uptake of PROTACs.

BackgroundIt is important that pharmacokinetic (PK) prediction methods are validated, and also for compounds with varying physicochemical properties, molecular weights and PK characteristics.MethodsThe objective was to investigate how well the ANDROMEDA by Prosilico software predicts the clinical PK of four compounds of natural origin and with PK obstacles, not yet fully characterized PK, and/or inaccurate lab method-based predictions - colistin (negligible absorption, good metabolic stability, significant excretion), curucumin (low solubility, apparently poor bioavailability), UCN-01 (extremely high degree of plasma protein binding, metabolic stability, long half-life and poor PK prediction) and voclosporin (poorly understood PK).ResultsAll categorial predictions except one were correct, and the median prediction error was 2.5-fold. Largest prediction errors were found for the unbound fraction in plasma (>24-fold), clearance (178-fold) and half-life (90-fold) of UCN-01. Corresponding errors for clearance and half-life obtained with allometry were greater, 5800- and 145-fold, respectively. Extremely high affinity for alpha1-acid glycoprotein could explain these large prediction errors for this compound. A substantial amount of data and knowledge was added with the predictions.ConclusionDespite challenging compounds and PK, predictions were comparably good. The results further validated ANDROMEDA by Prosilico for human clinical PK-predictions.

Pharmacokinetic/toxicokinetic (PK/TK) information for chemicals in humans is generally lacking. Here we applied machine learning, conformal prediction and a new physiologically-based PK/TK model for prediction of the human PK/TK of 65 chemicals from different classes, including carcinogens, food constituents and preservatives, vitamins, sweeteners, dyes and colours, pesticides, alternative medicines, flame retardants, psychoactive drugs, dioxins, poisons, UV-absorbents, surfactants, solvents and cosmetics.About 80% of the main human PK/TK (fraction absorbed, oral bioavailability, half-life, unbound fraction in plasma, clearance, volume of distribution, fraction excreted) for the selected chemicals was missing in the literature. This information was now added (from in silico predictions). Median and mean prediction errors for these parameters were 1.3- to 2.7-fold and 1.4- to 4.8-fold, respectively. In total, 59 and 86% of predictions had errors in silico predictions). Median and mean prediction errors for these parameters were 1.3- to 2.7-fold and 1.4- to 4.8-fold, respectively. In total, 59 and 86% of predictions had errors

By providing increased robustness to failure and reproducibility of results, workflows are an established workhorse of computer-aided science as well as an increasingly important part also in data pipelines in industry. For such complex and dynamic needs, we argue for the benefits of workflows implemented as computer programs, using workflow tools implemented as programming libraries. Furthermore, by using flow-based programming principles, a declarative while programmatic API can be presented, while still hiding a lot of low-level details under the hood. Being able to provide workflows in the form of compiled executable files has benefits both for the ease of deployment and future reproducibility. Workflow tool implementations are at risk for bit rot or incompatible changes well before the mainstream programming languages -or processor architectures -are.

One of the challenges with predictive modeling is how to quantify the reliability of the models' predictions on new objects. In this work we give an introduction to conformal prediction, a framework that sits on top of traditional machine learning algorithms and which outputs valid confidence estimates to predictions from QSAR models in the form of prediction intervals that are specific to each predicted object. For regression, a prediction interval consists of an upper and a lower bound. For classification, a prediction interval is a set that contains none, one, or many of the potential classes. The size of the prediction interval is affected by a user-specified confidence/significance level, and by the nonconformity of the predicted object; i.e., the strangeness as defined by a nonconformity function. Conformal prediction provides a rigorous and mathematically proven framework for in silico modeling with guarantees on error rates as well as a consistent handling of the models' applicability domain intrinsically linked to the underlying machine learning model. Apart from introducing the concepts and types of conformal prediction, we also provide an example application for modeling ABC transporters using conformal prediction, as well as a discussion on general implications for drug discovery.

Although medical cancer treatment has improved during the past decades, it is difficult to choose between several first-line treatments supposed to be equally active in the diagnostic group. It is even more difficult to select a treatment after the standard protocols have failed. Any guidance for selection of the most effective treatment is valuable at these critical stages. We describe the principles and procedures for ex vivo assessment of drug activity in tumor cells from patients as a basis for tailored cancer treatment. Patient tumor cells are assayed for cytotoxicity with a panel of drugs. Acoustic drug dispensing provides great flexibility in the selection of drugs for testing; currently, up to 80 compounds and/or combinations thereof may be tested for each patient. Drug response predictions are obtained by classification using an empirical model based on historical responses for the diagnosis. The laboratory workflow is supported by an integrated system that enables rapid analysis and automatic generation of the clinical referral response.

BackgroundThe complex nature of biological data has driven the development of specialized software tools. Scientific workflow management systems simplify the assembly of such tools into pipelines, assist with job automation and aid reproducibility of analyses. Many contemporary workflow tools are specialized and not designed for highly complex workflows, such as with nested loops, dynamic scheduling and parametriza-tion, which is common in e.g. machine learning.FindingsSciPipe is a workflow programming library implemented in the programming language Go, for managing complex and dynamic pipelines in bioinformatics, cheminformatics and other fields. SciPipe helps in particular with workflow constructs common in machine learning, such as extensive branching, parameter sweeps and dynamic scheduling and parametrization of downstream tasks. SciPipe builds on Flow-based programming principles to support agile development of workflows based on a library of self-contained, reusable components. It supports running subsets of workflows for improved iterative development, and provides a data-centric audit logging feature that saves a full audit trace for every output file of a workflow, which can be converted to other formats such as HTML, TeX and PDF on-demand. The utility of SciPipe is demonstrated with a machine learning pipeline, a genomics, and a transcriptomics pipeline.ConclusionsSciPipe provides a solution for agile development of complex and dynamic pipelines, espe-cially in machine leaning, through a flexible programming API suitable for scientists used to programming or scripting.

Ligand-based models can be used in drug discovery to obtain an early indication of potential off-target interactions that could be linked to adverse effects. Another application is to combine such models into a panel, allowing to compare and search for compounds with similar profiles. Most contemporary methods and implementations however lack valid measures of confidence in their predictions, and only provide point predictions. We here describe a methodology that uses Conformal Prediction for predicting off-target interactions, with models trained on data from 31 targets in the ExCAPE-DB dataset selected for their utility in broad early hazard assessment. Chemicals were represented by the signature molecular descriptor and support vector machines were used as the underlying machine learning method. By using conformal prediction, the results from predictions come in the form of confidence p-values for each class. The full pre-processing and model training process is openly available as scientific workflows on GitHub, rendering it fully reproducible. We illustrate the usefulness of the developed methodology on a set of compounds extracted from DrugBank. The resulting models are published online and are available via a graphical web interface and an OpenAPI interface for programmatic access.

Background The Chemistry Development Kit (CDK) is a widely used open source cheminformatics toolkit, providing data structures to represent chemical concepts along with methods to manipulate such structures and perform computations on them. The library implements a wide variety of cheminformatics algorithms ranging from chemical structure canonicalization to molecular descriptor calculations and pharmacophore perception. It is used in drug discovery, metabolomics, and toxicology. Over the last 10 years, the code base has grown significantly, however, resulting in many complex interdependencies among components and poor performance of many algorithms. Results We report improvements to the CDK v2.0 since the v1.2 release series, specifically addressing the increased functional complexity and poor performance. We first summarize the addition of new functionality, such atom typing and molecular formula handling, and improvement to existing functionality that has led to significantly better performance for substructure searching, molecular fingerprints, and rendering of molecules. Second, we outline how the CDK has evolved with respect to quality control and the approaches we have adopted to ensure stability, including a code review mechanism. Conclusions This paper highlights our continued efforts to provide a community driven, open source cheminformatics library, and shows that such collaborative projects can thrive over extended periods of time, resulting in a high-quality and performant library. By taking advantage of community support and contributions, we show that an open source cheminformatics project can act as a peer reviewed publishing platform for scientific computing software.Graphical abstractCDK 2.0 provides new features and improved performance Electronic supplementary material The online version of this article (doi:10.1186/s13321-017-0220-4) contains supplementary material, which is available to authorized users.

QSAR modeling using molecular signatures and support vector machines with a radial basis function is increasingly used for virtual screening in the drug discovery field. This method has three free parameters: C, γ, and signature height. C is a penalty parameter that limits overfitting, γ controls the width of the radial basis function kernel, and the signature height determines how much of the molecule is described by each atom signature. Determination of optimal values for these parameters is time-consuming. Good default values could therefore save considerable computational cost. The goal of this project was to investigate whether such default values could be found by using seven public QSAR data sets spanning a wide range of end points and using both a bit version and a count version of the molecular signatures. On the basis of the experiments performed, we recommend a parameter set of heights 0 to 2 for the count version of the signature fingerprints and heights 0 to 3 for the bit version. These are in combination with a support vector machine using C in the range of 1 to 100 and γ in the range of 0.001 to 0.1. When data sets are small or longer run times are not a problem, then there is reason to consider the addition of height 3 to the count fingerprint and a wider grid search. However, marked improvements should not be expected.

Predictive modelling in drug discovery is challenging to automate as it often contains multiple analysis steps and might involve cross-validation and parameter tuning that create complex dependencies between tasks. With large-scale data or when using computationally demanding modelling methods, e-infrastructures such as high-performance or cloud computing are required, adding to the existing challenges of fault-tolerant automation. Workflow management systems can aid in many of these challenges, but the currently available systems are lacking in the functionality needed to enable agile and flexible predictive modelling. We here present an approach inspired by elements of the flow-based programming paradigm, implemented as an extension of the Luigi system which we name SciLuigi. We also discuss the experiences from using the approach when modelling a large set of biochemical interactions using a shared computer cluster.Graphical abstract.

The increasing size of datasets in drug discovery makes it challenging to build robust and accurate predictive models within a reasonable amount of time. In order to investigate the effect of dataset sizes on predictive performance and modelling time, ligand-based regression models were trained on open datasets of varying sizes of up to 1.2 million chemical structures. For modelling, two implementations of support vector machines (SVM) were used. Chemical structures were described by the signatures molecular descriptor. Results showed that for the larger datasets, the LIBLINEAR SVM implementation performed on par with the well-established libsvm with a radial basis function kernel, but with dramatically less time for model building even on modest computer resources. Using a non-linear kernel proved to be infeasible for large data sizes, even with substantial computational resources on a computer cluster. To deploy the resulting models, we extended the Bioclipse decision support framework to support models from LIBLINEAR and made our models of logD and solubility available from within Bioclipse. Electronic supplementary material The online version of this article (doi:10.1186/s13321-016-0151-5) contains supplementary material, which is available to authorized users.

Summary: Bioclipse, a graphical workbench for the life sciences, provides functionality for managing and visualizing life science data. We introduce Bioclipse-R, which integrates Bioclipse and the statistical programming language R. The synergy between Bioclipse and R is demonstrated by the construction of a decision support system for anticancer drug screening and mutagenicity prediction, which shows how Bioclipse-R can be used to perform complex tasks from within a single software system. Availability and implementation: Bioclipse-R is implemented as a set of Java plug-ins for Bioclipse based on the R-package rj. Source code and binary packages are available from https://github.com/bioclipse and http://www.bioclipse.net/bioclipse-r, respectively. Contact: martin.eklund@farmbio.uu.se Supplementary information: Supplementary data are available at Bioinformatics online.

Growing data sets with increased time for analysis is hampering predictive modeling in drug discovery. Model building can be carried out on high-performance computer clusters, but these can be expensive to purchase and maintain. We have evaluated ligand-based modeling on cloud computing resources where computations are parallelized and run on the Amazon Elastic Cloud. We trained models on open data sets of varying sizes for the end points logP and Ames mutagenicity and compare with model building parallelized on a traditional high-performance computing cluster. We show that while high-performance computing results in faster model building, the use of cloud computing resources is feasible for large data sets and scales well within cloud instances. An additional advantage of cloud computing is that the costs of predictive models can be easily quantified, and a choice can be made between speed and economy. The easy access to computational resources with no up-front investments makes cloud computing an attractive alternative for scientists, especially for those without access to a supercomputer, and our study shows that it enables cost-efficient modeling of large data sets on demand within reasonable time.

When evaluating a potential drug candidate it is desirable to predict target interactions in silico prior to synthesis in order to assess, e.g., secondary pharmacology. This can be done by looking at known target binding profiles of similar compounds using chemical similarity searching. The purpose of this study was to construct and evaluate the performance of chemical fingerprints based on the molecular signature descriptor for performing target binding predictions. For the comparison we used the area under the receiver operating characteristics curve (AUC) complemented with net reclassification improvement (NRI). We created two open source signature fingerprints, a bit and a count version, and evaluated their performance compared to a set of established fingerprints with regards to predictions of binding targets using Tanimoto-based similarity searching on publicly available data sets extracted from ChEMBL. The results showed that the count version of the signature fingerprint performed on par with well-established fingerprints such as ECFP. The count version outperformed the bit version slightly; however, the count version is more complex and takes more computing time and memory to run so its usage should probably be evaluated on a case-by-case basis. The NRI based tests complemented the AUC based ones and showed signs of higher power.

We present the open source components for drug discovery that has been developed and integrated into the graphical workbench Bioclipse. Building on a solid open source cheminformatics core, Bioclipse has advanced functionality for managing and visualizing chemical structures and related information. The features presented here include QSAR/QSPR modeling, various predictive solutions such as decision support for chemical liability assessment, site-ofmetabolism prediction, virtual screening, and knowledge discovery and integration. We demonstrate the utility of the described tools with examples from computational pharmacology, toxicology, and ADME. Bioclipse is used in both academia and industry, and is a good example of open source leading to new solutions for drug discovery.

We present the open source components for drug discovery that has been developed and integrated into the graphical workbench Bioclipse. Building on a solid open source cheminformatics core, Bioclipse has advanced functionality for managing and visualizing chemical structures and related information. The features presented here include QSAR/QSPR modeling, various predictive solutions such as decision support for chemical liability assessment, site-ofmetabolism prediction, virtual screening, and knowledge discovery and integration. We demonstrate the utility of the described tools with examples from computational pharmacology, toxicology, and ADME. Bioclipse is used in both academia and industry, and is a good example of open source leading to new solutions for drug discovery.

Background The Blue Obelisk movement was established in 2005 as a response to the lack of Open Data, Open Standards and Open Source (ODOSOS) in chemistry. It aims to make it easier to carry out chemistry research by promoting interoperability between chemistry software, encouraging cooperation between Open Source developers, and developing community resources and Open Standards. Results This contribution looks back on the work carried out by the Blue Obelisk in the past 5 years and surveys progress and remaining challenges in the areas of Open Data, Open Standards, and Open Source in chemistry. Conclusions We show that the Blue Obelisk has been very successful in bringing together researchers and developers with common interests in ODOSOS, leading to development of many useful resources freely available to the chemistry community.

Background Compound profiling and drug screening generates large amounts of data and is generally based on microplate assays. Current information systems used for handling this are mainly commercial, closed source, expensive, and heavyweight and there is a need for a flexible lightweight open system for handling plate design, and validation and preparation of data. Results A Bioclipse plugin consisting of a client part and a relational database was constructed. A multiple-step plate layout point-and-click interface was implemented inside Bioclipse. The system contains a data validation step, where outliers can be removed, and finally a plate report with all relevant calculated data, including dose-response curves. Conclusions Brunn is capable of handling the data from microplate assays. It can create dose-response curves and calculate IC50 values. Using a system of this sort facilitates work in the laboratory. Being able to reuse already constructed plates and plate layouts by starting out from an earlier step in the plate layout design process saves time and cuts down on error sources.

Background Contemporary biological research integrates neighboring scientific domains to answer complex questions in fields such as systems biology and drug discovery. This calls for tools that are intuitive to use, yet flexible to adapt to new tasks. Results Bioclipse is a free, open source workbench with advanced features for the life sciences. Version 2.0 constitutes a complete rewrite of Bioclipse, and delivers a stable, scalable integration platform for developers and an intuitive workbench for end users. All functionality is available both from the graphical user interface and from a built-in novel domain-specific language, supporting the scientist in interdisciplinary research and reproducible analyses through advanced visualization of the inputs and the results. New components for Bioclipse 2 include a rewritten editor for chemical structures, a table for multiple molecules that supports gigabyte-sized files, as well as a graphical editor for sequences and alignments. Conclusion Bioclipse 2 is equipped with advanced tools required to carry out complex analysis in the fields of bio- and cheminformatics. Developed as a Rich Client based on Eclipse, Bioclipse 2 leverages on today's powerful desktop computers for providing a responsive user interface, but also takes full advantage of the Web and networked (Web/Cloud) services for more demanding calculations or retrieval of data. The fact that Bioclipse 2 is based on an advanced and widely used service platform ensures wide extensibility, making it easy to add new algorithms, visualizations, as well as scripting commands. The intuitive tools for end users and the extensible architecture make Bioclipse 2 ideal for interdisciplinary and integrative research. Bioclipse 2 is released under the Eclipse Public License (EPL), a flexible open source license that allows additional plugins to be of any license. Bioclipse 2 is implemented in Java and supported on all major platforms; Source code and binaries are freely available at http://www.bioclipse.net.

Background Semantic web technologies are finding their way into the life sciences. Ontologies and semantic markup have already been used for more than a decade in molecular sciences, but have not found widespread use yet. The semantic web technology Resource Description Framework (RDF) and related methods show to be sufficiently versatile to change that situation. Results The work presented here focuses on linking RDF approaches to existing molecular chemometrics fields, including cheminformatics, QSAR modeling and proteochemometrics. Applications are presented that link RDF technologies to methods from statistics and cheminformatics, including data aggregation, visualization, chemical identification, and property prediction. They demonstrate how this can be done using various existing RDF standards and cheminformatics libraries. For example, we show how IC50 and Ki values are modeled for a number of biological targets using data from the ChEMBL database. Conclusions We have shown that existing RDF standards can suitably be integrated into existing molecular chemometrics methods. Platforms that unite these technologies, like Bioclipse, makes this even simpler and more transparent. Being able to create and share workflows that integrate data aggregation and analysis (visual and statistical) is beneficial to interoperability and reproducibility. The current work shows that RDF approaches are sufficiently powerful to support molecular chemometrics workflows.